Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer
Randomized Phase II Trial of Paclitaxel, Carboplatin and rhuMAb Her-2 (Herceptin) as First-Line Chemotherapy in Patients With Metastatic Breast Cancer Who Overexpress Her-2
Sponsor: Alliance for Clinical Trials in Oncology
This PHASE2 trial investigates Breast Cancer and is currently completed. Alliance for Clinical Trials in Oncology leads this study, which shows 8 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States, Bismarck, United States, Cedar Rapids, United States, Danville, United States, Des Moines, United States, Duluth, United States, Fargo, United States, Grand Forks, United States, Green Bay, United States, Jacksonville, United States and 14 more location s